Extract
Mycobacterium avium complex pulmonary disease (MAC-PD) is an increasing problem worldwide [1]. The American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines recommend a macrolide-ethambutol-rifamycin combination as first-line treatment for MAC-PD (standard triple therapy) [2]. This therapy results in microbiological success in only 52–60% of patients [3, 4]. Treatment discontinuation or modification due to toxicity is common [5, 6]. Fluoroquinolones (FQs) are frequently prescribed for MAC-PD [7]. Although favorable activity has been shown in vitro and in mouse models [8], there is little clinical evidence supporting their efficacy and safety for MAC-PD [9–11]. We sought to investigate treatment outcomes and adverse events among MAC-PD patients treated with fluoroquinolone-containing therapy versus standard triple therapy.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Khadawardi has nothing to disclose.
Conflict of interest: Dr. Marras has nothing to disclose.
Conflict of interest: Dr. Mehrabi has nothing to disclose.
Conflict of interest: Dr. Brode has nothing to disclose.
- Received June 22, 2019.
- Accepted December 29, 2019.
- Copyright ©ERS 2020
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org